FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2926356219> ?p ?o ?g. }

• W2926356219 endingPage "9" @default.
• W2926356219 startingPage "2" @default.
• W2926356219 abstract "BackgroundSeveral randomized controlled trials have demonstrated that preoperative abdominal skin preparation with chlorhexidine gluconate is superior to povidone-iodine for the prevention of surgical site infections. Despite these results, povidone-iodine is still the most commonly used agent for vaginal preparation, even though it may not be ideal.ObjectivesThe objectives of the study were as follows: (1) to determine whether vaginal cleansing with a 4% chlorhexidine gluconate solution results in fewer wound infections as compared with povidone-iodine when used for vaginal antisepsis prior to cesarean delivery and (2) to compare rates of patient reported side-effects associated with vaginal application of 4% chlorhexidine gluconate solution and 10% povidone-iodine.Study DesignThis is a block randomized, comparator-controlled, open-label trial. Women undergoing nonemergent cesarean delivery were randomized to receive vaginal cleansing with either 4% chlorhexidine solution or 10% povidone-iodine solution prior to skin incision. The primary outcome was wound site infection occurring within 14 days of cesarean delivery including superficial or deep surgical site infection. Secondary outcomes included rates of endometritis, postoperative fever, and side effects (vaginal dryness, irritation, and desquamitization) occurring within 14 days of cesarean delivery. Risks were reported as odds ratios with 95% confidence intervals, with P < .05 considered as significant.ResultsFrom Dec. 1, 2016, through Feb. 28, 2018, a total of 1,114 patients met the inclusion criteria: 524 were randomized to the chlorhexidine gluconate arm and 590 to the povidone-iodine arm. Both arms were similar with regard to age, parity, body mass index, gestational age at delivery, indication for cesarean delivery, and incidence of membrane rupture. The rate of wound infection was significantly lower in the chlorhexidine arm as compared with povidone-iodine (0.6% vs 2.0%; P = .039, odds ratio, 0.28, 95% confidence interval, 0.08–0.98). Rates of endometritis (0.4% vs 0.5%, P = 1.000) and postoperative fever (2.5% and 2.7%, P = 0.892) were similar for the chlorhexidine and povidone-iodine groups, respectively. No adverse effects on the vaginal mucosa were noted for either solution.ConclusionVaginal cleansing with a 4% chlorhexidine solution prior to cesarean delivery resulted in fewer overall wound infections when compared with povidone-iodine solution with no patient-reported adverse reactions. Several randomized controlled trials have demonstrated that preoperative abdominal skin preparation with chlorhexidine gluconate is superior to povidone-iodine for the prevention of surgical site infections. Despite these results, povidone-iodine is still the most commonly used agent for vaginal preparation, even though it may not be ideal. The objectives of the study were as follows: (1) to determine whether vaginal cleansing with a 4% chlorhexidine gluconate solution results in fewer wound infections as compared with povidone-iodine when used for vaginal antisepsis prior to cesarean delivery and (2) to compare rates of patient reported side-effects associated with vaginal application of 4% chlorhexidine gluconate solution and 10% povidone-iodine. This is a block randomized, comparator-controlled, open-label trial. Women undergoing nonemergent cesarean delivery were randomized to receive vaginal cleansing with either 4% chlorhexidine solution or 10% povidone-iodine solution prior to skin incision. The primary outcome was wound site infection occurring within 14 days of cesarean delivery including superficial or deep surgical site infection. Secondary outcomes included rates of endometritis, postoperative fever, and side effects (vaginal dryness, irritation, and desquamitization) occurring within 14 days of cesarean delivery. Risks were reported as odds ratios with 95% confidence intervals, with P < .05 considered as significant. From Dec. 1, 2016, through Feb. 28, 2018, a total of 1,114 patients met the inclusion criteria: 524 were randomized to the chlorhexidine gluconate arm and 590 to the povidone-iodine arm. Both arms were similar with regard to age, parity, body mass index, gestational age at delivery, indication for cesarean delivery, and incidence of membrane rupture. The rate of wound infection was significantly lower in the chlorhexidine arm as compared with povidone-iodine (0.6% vs 2.0%; P = .039, odds ratio, 0.28, 95% confidence interval, 0.08–0.98). Rates of endometritis (0.4% vs 0.5%, P = 1.000) and postoperative fever (2.5% and 2.7%, P = 0.892) were similar for the chlorhexidine and povidone-iodine groups, respectively. No adverse effects on the vaginal mucosa were noted for either solution. Vaginal cleansing with a 4% chlorhexidine solution prior to cesarean delivery resulted in fewer overall wound infections when compared with povidone-iodine solution with no patient-reported adverse reactions." @default.
• W2926356219 created "2019-04-11" @default.
• W2926356219 creator A5003450432 @default.
• W2926356219 creator A5016096365 @default.
• W2926356219 creator A5018332364 @default.
• W2926356219 creator A5078547734 @default.
• W2926356219 date "2019-03-01" @default.
• W2926356219 modified "2023-10-16" @default.
• W2926356219 title "Vaginal cleansing with chlorhexidine gluconate or povidone-iodine prior to cesarean delivery: a randomized comparator-controlled trial" @default.
• W2926356219 cites W1771339314 @default.
• W2926356219 cites W1998605536 @default.
• W2926356219 cites W2000862853 @default.
• W2926356219 cites W2005217771 @default.
• W2926356219 cites W2015182853 @default.
• W2926356219 cites W2044304572 @default.
• W2926356219 cites W2073321443 @default.
• W2926356219 cites W2077174371 @default.
• W2926356219 cites W2109189914 @default.
• W2926356219 cites W2130314377 @default.
• W2926356219 cites W2158466965 @default.
• W2926356219 cites W2269831675 @default.
• W2926356219 cites W2315032641 @default.
• W2926356219 cites W2508897128 @default.
• W2926356219 cites W2524784252 @default.
• W2926356219 cites W2610936380 @default.
• W2926356219 cites W2624113091 @default.
• W2926356219 cites W2744371561 @default.
• W2926356219 cites W2764042589 @default.
• W2926356219 cites W2798795107 @default.
• W2926356219 cites W2831382032 @default.
• W2926356219 cites W2885928060 @default.
• W2926356219 cites W4237687360 @default.
• W2926356219 cites W4241246898 @default.
• W2926356219 doi "https://doi.org/10.1016/j.ajogmf.2019.03.004" @default.
• W2926356219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33319753" @default.
• W2926356219 hasPublicationYear "2019" @default.
• W2926356219 type Work @default.
• W2926356219 sameAs 2926356219 @default.
• W2926356219 citedByCount "14" @default.
• W2926356219 countsByYear W29263562192019 @default.
• W2926356219 countsByYear W29263562192020 @default.
• W2926356219 countsByYear W29263562192021 @default.
• W2926356219 countsByYear W29263562192022 @default.
• W2926356219 countsByYear W29263562192023 @default.
• W2926356219 crossrefType "journal-article" @default.
• W2926356219 hasAuthorship W2926356219A5003450432 @default.
• W2926356219 hasAuthorship W2926356219A5016096365 @default.
• W2926356219 hasAuthorship W2926356219A5018332364 @default.
• W2926356219 hasAuthorship W2926356219A5078547734 @default.
• W2926356219 hasConcept C126322002 @default.
• W2926356219 hasConcept C141071460 @default.
• W2926356219 hasConcept C142724271 @default.
• W2926356219 hasConcept C156957248 @default.
• W2926356219 hasConcept C168563851 @default.
• W2926356219 hasConcept C191897082 @default.
• W2926356219 hasConcept C192562407 @default.
• W2926356219 hasConcept C199343813 @default.
• W2926356219 hasConcept C204787440 @default.
• W2926356219 hasConcept C27081682 @default.
• W2926356219 hasConcept C2775846227 @default.
• W2926356219 hasConcept C2777084678 @default.
• W2926356219 hasConcept C2779234561 @default.
• W2926356219 hasConcept C2781460226 @default.
• W2926356219 hasConcept C2991686891 @default.
• W2926356219 hasConcept C42219234 @default.
• W2926356219 hasConcept C44249647 @default.
• W2926356219 hasConcept C539932907 @default.
• W2926356219 hasConcept C54355233 @default.
• W2926356219 hasConcept C71924100 @default.
• W2926356219 hasConcept C86803240 @default.
• W2926356219 hasConceptScore W2926356219C126322002 @default.
• W2926356219 hasConceptScore W2926356219C141071460 @default.
• W2926356219 hasConceptScore W2926356219C142724271 @default.
• W2926356219 hasConceptScore W2926356219C156957248 @default.
• W2926356219 hasConceptScore W2926356219C168563851 @default.
• W2926356219 hasConceptScore W2926356219C191897082 @default.
• W2926356219 hasConceptScore W2926356219C192562407 @default.
• W2926356219 hasConceptScore W2926356219C199343813 @default.
• W2926356219 hasConceptScore W2926356219C204787440 @default.
• W2926356219 hasConceptScore W2926356219C27081682 @default.
• W2926356219 hasConceptScore W2926356219C2775846227 @default.
• W2926356219 hasConceptScore W2926356219C2777084678 @default.
• W2926356219 hasConceptScore W2926356219C2779234561 @default.
• W2926356219 hasConceptScore W2926356219C2781460226 @default.
• W2926356219 hasConceptScore W2926356219C2991686891 @default.
• W2926356219 hasConceptScore W2926356219C42219234 @default.
• W2926356219 hasConceptScore W2926356219C44249647 @default.
• W2926356219 hasConceptScore W2926356219C539932907 @default.
• W2926356219 hasConceptScore W2926356219C54355233 @default.
• W2926356219 hasConceptScore W2926356219C71924100 @default.
• W2926356219 hasConceptScore W2926356219C86803240 @default.
• W2926356219 hasIssue "1" @default.
• W2926356219 hasLocation W29263562191 @default.
• W2926356219 hasOpenAccess W2926356219 @default.
• W2926356219 hasPrimaryLocation W29263562191 @default.
• W2926356219 hasRelatedWork W157063861 @default.
• W2926356219 hasRelatedWork W1910050651 @default.
• W2926356219 hasRelatedWork W2034534016 @default.

• next